Učitavanje...
A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
Phosphatidylinositol 3-kinase δ (PIK3δ) is a tyrosine kinase essential for B cell survival, making it an important target in the treatment of chronic lymphocytic leukemia. Idelalisib is an inhibitor of PIK3δ demonstrating initial success in disease response, but is now shown to have a decreased over...
Spremljeno u:
| Izdano u: | J Investig Med High Impact Case Rep |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5446100/ https://ncbi.nlm.nih.gov/pubmed/28589155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2324709617711463 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|